Point72 Hong Kong LTD Tcr2 Therapeutics Inc. Transaction History

Point72 Hong Kong LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$1.86 - $3.75 $3,238 - $6,528	1,741 New	1,741 $3,000
Q2 2022 Aug 15, 2022	SELL	$2.11 - $2.94 $4,802 - $6,691	-2,276 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$2.4 - $4.71 $12,691 - $24,906	-5,288 Reduced 69.91%	2,276 $6,000
Q4 2021 Feb 14, 2022	SELL	$4.58 - $8.34 $15,842 - $28,848	-3,459 Reduced 31.38%	7,564 $35,000
Q3 2021 Nov 15, 2021	BUY	$8.44 - $18.35 $78,880 - $171,499	9,346 Added 557.3%	11,023 $94,000
Q2 2021 Aug 16, 2021	SELL	$16.41 - $24.71 $3,807 - $5,732	-232 Reduced 12.15%	1,677 $28,000
Q1 2021 May 17, 2021	BUY	$20.38 - $34.07 $38,905 - $65,039	1,909 New	1,909 $42,000

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Point72 Hong Kong LTD, based on Form 13F filings with the SEC.

Stay updated on Point72 Hong Kong LTD with notifications on news.